GCG and Hypoglycemia: Against this background our results are somewhat surprising especially in comparison to analyses predicting anamnestic hypoglycaemia in DiaRegis but have to be weighed against a number of changes that were introduced over the course of 12 months: 1) sulfonylurea use was reduced between baseline and the 12 months follow-up from 29.5 to 24.2%, at least partially also because of hypoglycaemia; 2) oral monotherapy went down from 68.4% at baseline to 17.8% at the 1 year FU in favour of combined OAD treatment regimens and insulin / GLP-1 analogue use.